Related Experiment Video
Updated: Jun 13, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Heteroresistance of Cryptococcus gattii to fluconazole
1Molecular Microbiology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Abstract:
We analyzed 71 clinical and environmental Cryptococcus gattii strains that had been isolated before or after the advent of azole antifungals to determine their level of heteroresistance to fluconazole (LHF). All strains of C. gattii manifested heteroresistance, with LHFs that ranged between 4 microg/ml and 32 microg/ml. A considerably higher proportion of the C. gattii strains (86%) than Cryptococcus neoformans strains (46%) exhibited LHFs that were > or =16 microg/ml. No significant correlation was observed between the molecular type or serotypes of strains and their respective LHF. The strains which expressed a higher LHF were also more resistant to xenobiotics than the strains with a low LHF, and the level of resistance to xenobiotics was significantly higher than that reported for C. neoformans. The heteroresistant subpopulation, whose level of drug resistance had been raised in a stepwise manner to 64 microg/ml, reverted to the original LHF upon daily transfers in drug-free medium. Importantly, the strains with high LHFs were significantly more virulent than those with low LHFs. Since all the clinical isolates that had not been exposed to azole drugs as well as the environmental strains manifested heteroresistance to fluconazole, heteroresistance of C. gattii to azoles is an intrinsic mechanism as in C. neoformans and is associated with the strain's virulence.
Insights
All Cryptococcus gattii strains exhibit fluconazole heteroresistance, an intrinsic trait linked to increased virulence. This antifungal resistance mechanism is present even in strains not previously exposed to azoles.
Area of Science:
- Mycology
- Antimicrobial Resistance
- Infectious Diseases
Background:
- Cryptococcus gattii is an emerging fungal pathogen causing cryptococcosis.
- Azole antifungals are key treatments, but resistance can develop.
- Heteroresistance, a form of drug tolerance, is a known mechanism in Cryptococcus neoformans.
Purpose of the Study:
- To determine the level of fluconazole heteroresistance (LHF) in Cryptococcus gattii strains.
- To investigate the correlation between LHF, xenobiotic resistance, and virulence.
- To ascertain if LHF is an intrinsic characteristic of C. gattii.
Main Methods:
- Analysis of 71 clinical and environmental C. gattii strains.
- Determination of fluconazole heteroresistance levels (LHF).
- Assessment of xenobiotic resistance and virulence in relation to LHF.
Main Results:
- All C. gattii strains showed heteroresistance to fluconazole, with LHFs ranging from 4 to 32 microg/ml.
- 86% of C. gattii strains had LHFs >=16 microg/ml, compared to 46% of C. neoformans.
- Higher LHF correlated with increased xenobiotic resistance and significantly higher virulence.
- Heteroresistance reverted to baseline upon drug-free cultivation.
Conclusions:
- Fluconazole heteroresistance is an intrinsic trait in C. gattii, similar to C. neoformans.
- This intrinsic heteroresistance is associated with increased fungal virulence.
- Understanding LHF is crucial for managing C. gattii infections and antifungal therapy.
Related Concept Videos
Cryptococcal Meningitis
Antifungal Agents
Candidiasis
Inhibitors of Bacterial DNA Synthesis

